Alx Oncology Holdings
Price & Volume
Stats
See moreOpen | $1.91 |
Previous Close | $1.92 |
Day Range | $1.86-$1.91 |
52W Range | $1.03-$2.66 |
Market Cap | $268.2M |
Shares Short | 7M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | -100% |
Gross Profit (12 Mos) | $107,000 |
Diluted EPS | -$1.15 |
News
See moreYahoo Finance • 4 months ago
Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS
Yahoo Finance • 5 months ago
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Yahoo Finance • 6 months ago
ALX Oncology initiated with a Buy at UBS
Yahoo Finance • 7 months ago
ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing
About
CEO | Mr. Jason W. Lettmann |
Address | 323 Allerton Avenue, South San Francisco, CA, United States, 94080 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 48 |